Investment Thesis

, a full position is supported, with an emphasis on monitoring key performance indicators and regulatory developments. A price decline below $140 or negative earnings surprises could prompt a reevaluation of the thesis, while strong earnings or favorable regulatory news could justify increasing the position.

Competitive Moat

characterized by significant scale economies and regulatory barriers associated with its operations in healthcare services. The company’s established network of 2,815 outpatient dialysis centers and additional international presence creates substantial switching costs for patients, who rely heavily on continuity of care. Over the next 5-10 years, this moat is expected to remain durable, although potential threats include increasing competition from emerging dialysis service providers and innovations in kidney disease treatment that could disrupt traditional dialysis methods.

Growth Engine

Future revenue growth for DaVita is largely driven by the expanding total addressable market (TAM) for renal care as the prevalence of chronic kidney disease increases. With approximately 37 million adults in the U.S. affected by kidney disease, the potential for organic growth is significant as more patients require dialysis services. Additionally, DaVita's foray into integrated care arrangements and disease management services positions it to capture market share effectively. The company is not only maintaining but likely expanding its share within the dialysis market, aided by its comprehensive service offerings and strategic partnerships.